Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors
- PMID: 22245217
- DOI: 10.1016/j.ajpath.2011.11.035
Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors
Abstract
An important concept in tumor angiogenesis is that tumor endothelial cells (TECs) are genetically normal and homogeneous. However, we previously reported that TECs differ from normal ECs. Whether the characteristics of TECs derived from different tumors differ remains unknown. To elucidate this, in this study, we isolated two types of TECs from high-metastatic (HM) and low-metastatic (LM) tumors and compared their characteristics. HM tumor-derived TECs (HM-TECs) showed higher proliferative activity and invasive activity than LM tumor-derived TECs (LM-TECs). Moreover, the mRNA expression levels of pro-angiogenic genes, such as vascular endothelial growth factor (VEGF) receptors 1 and 2, VEGF, and hypoxia-inducible factor-1α, were higher in HM-TECs than in LM-TECs. The tumor blood vessels themselves and the surrounding area in HM tumors were exposed to hypoxia. Furthermore, HM-TECs showed higher mRNA expression levels of the stemness-related gene stem cell antigen and the mesenchymal marker CD90 compared with LM-TECs. HM-TECs were spheroid, with a smoother surface and higher circularity in the stem cell spheroid assay. HM-TECs differentiated into osteogenic cells, expressing activated alkaline phosphatase in an osteogenic medium at a higher rate than either LM-TECs or normal ECs. Furthermore, HM-TECs contained more aneuploid cells than LM-TECs. These results indicate that TECs from HM tumors have a more pro-angiogenic phenotype than those from LM tumors.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype.PLoS One. 2014 Dec 1;9(12):e113910. doi: 10.1371/journal.pone.0113910. eCollection 2014. PLoS One. 2014. PMID: 25437864 Free PMC article.
-
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Jpn J Cancer Res. 1996 Sep;87(9):963-71. doi: 10.1111/j.1349-7006.1996.tb02127.x. Jpn J Cancer Res. 1996. PMID: 8878460 Free PMC article.
-
Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment.Am J Pathol. 2012 Mar;180(3):1283-1293. doi: 10.1016/j.ajpath.2011.11.029. Epub 2012 Jan 13. Am J Pathol. 2012. PMID: 22245726
-
Tumour endothelial cells acquire drug resistance in a tumour microenvironment.J Biochem. 2013 Mar;153(3):243-9. doi: 10.1093/jb/mvs152. Epub 2013 Jan 3. J Biochem. 2013. PMID: 23293323 Review.
-
Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis.Cells. 2020 Jun 24;9(6):1539. doi: 10.3390/cells9061539. Cells. 2020. PMID: 32599893 Free PMC article. Review.
Cited by
-
Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.Cancers (Basel). 2018 Aug 30;10(9):295. doi: 10.3390/cancers10090295. Cancers (Basel). 2018. PMID: 30200265 Free PMC article. Review.
-
Endothelial Cells (ECs) Metabolism: A Valuable Piece to Disentangle Cancer Biology.Adv Exp Med Biol. 2020;1219:143-159. doi: 10.1007/978-3-030-34025-4_8. Adv Exp Med Biol. 2020. PMID: 32130698 Review.
-
Aberrant tumor vasculature. Facts and pitfalls.Front Pharmacol. 2024 Mar 21;15:1384721. doi: 10.3389/fphar.2024.1384721. eCollection 2024. Front Pharmacol. 2024. PMID: 38576482 Free PMC article. Review.
-
Endothelial cell metabolism in normal and diseased vasculature.Circ Res. 2015 Mar 27;116(7):1231-44. doi: 10.1161/CIRCRESAHA.116.302855. Circ Res. 2015. PMID: 25814684 Free PMC article. Review.
-
Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.Cancer Sci. 2022 May;113(5):1855-1867. doi: 10.1111/cas.15323. Epub 2022 Mar 21. Cancer Sci. 2022. PMID: 35266253 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources